Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP 6: Semaglutide in East Asian Adults with Overweight or Obesity
NCT03811574Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2019
- Primary completion
- Nov 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of semaglutide in obesity and Overweight (4 arms), sponsored by Novo Nordisk. Primary endpoints: Change in Body Weight at 68 weeks and Proportion of Participants Achieving >= 5% Weight Reduction at 68 weeks. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03811574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03811574.